Medtronic is developing a robotic-assisted surgery system that needs regulatory approval in the US, amidst aggressive trade policy threats.
2 reports, 1 independent
Updated Aug 5
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Medtronic is developing a robotic-assisted surgery system that needs regulatory approval in the US, amidst aggressive trade policy threats.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Corporate activity in the medical device sector in August 2025 included M&A activity (Stryker/Inari Medical, ZimVie/Archimed), competition between Medtronic and Intuitive Surgical, and the impact of Trump administration tariffs and FDA reviews.Also in this story
- FDA approved Medtronic's Hugo robotic system for urological procedures, marking a major competitive shift in the medical device sector.
- Medtronic invested in Orchestra BioMed's clinical programs and provided private placement funding, while Ligand also invested in the company.
- Obagi Medical and Waldencast plc completed an acquisition expanding into dermal fillers and granting US rights to the Saypha line, while Trump-era tariffs benefit AI stocks.
- Intuitive Surgical invested in Apreo Health, whose device competes with Zephyr Valve, which was previously approved by the FDA.
The entities involved
-
Medtronic plc
medical device company
Related events
Coverage
Newest first; wire copies grouped- Motley Fool3 Reasons to Buy Medtronic Stock Medtronic is separating out its lower-margin diabetes care segment. It's also pouncing on a massive opportunity in robotic-assisted surgery. The healthcare leader has